Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Remdesivir is an approved antiviral treatment for COVID-19, but it needs to be administered intravenously. Here, Cox et al. show that GS-621763, a prodrug of remdesivir parent nucleoside GS-441524 has good oral bioavailability and inhibits SARS-CoV-2 and variants of concerns in ferrets.
Saved in:
Main Authors: | Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, Julien Sourimant, Michelle J. Lin, Darius Babusis, Venice DuPont, Julie Chan, Kim T. Barrett, Diane Lye, Rao Kalla, Kwon Chun, Richard L. Mackman, Chengjin Ye, Tomas Cihlar, Luis Martinez-Sobrido, Alexander L. Greninger, John P. Bilello, Richard K. Plemper |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/480b9bcf109e47b7bd2093b34d9f4683 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
by: Maria L. Agostini, et al.
Published: (2018) -
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524
by: Daniela Krentz, et al.
Published: (2021) -
The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance
by: Daisy Yan, et al.
Published: (2021) -
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
by: Timothy P. Sheahan, et al.
Published: (2020) -
Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
by: Travis K. Warren, et al.
Published: (2021)